MICROSOFT CORP

**Signal Note: Driehaus Capital Initiates MSFT Position** Driehaus's entry into MSFT (4,032 shares, $1.9M) likely reflects conviction in AI/computational biology applications rather than traditional biotech exposure. This aligns with the firm's growth mandate and suggests confidence in Microsoft's partnership with Illumina on genomics AI and potential expansion of Azure's drug discovery capabilities, though no near-term clinical catalysts are evident from this trade alone.